Source briefing
Early-Season Detection of Influenza A(H3N2) Subclade K in Wastewater, Colorado, USA, 2025–2026
M. C. Hetherington-Rauth et al.
Read →
Source briefing
CHMP opinions on consultation procedures on ancillary substances incorporated in a medical device
CHMP opinions on consultation procedures on ancillary substances incorporated in a medical device
Read →Source briefing
Medicine shortages and availability issues: guidance for companies
Medicine shortages and availability issues: guidance for companies
Read →
Source briefing
Human Myiasis Resulting from Reemergence of Cochliomyia hominivorax Screwworm, Mexico, 2025–2026
O. Delgado-Cuellar et al.
Read →Source briefing
Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised
Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised
Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Orblid, bevacizumab, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Orblid, bevacizumab, Status: Application withdrawn
Read →Source briefing
Human medicines European public assessment report (EPAR): Twinrix Adult, hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed), Date of authorisation: 19/09/1996, Revision: 25, Status: Authorised
Human medicines European public assessment report (EPAR): Twinrix Adult, hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed), Date of authorisation: 19/09/1996, Revision: 25, Status: Authorised
Read →Source briefing
Ninth European Medicines Agency (EMA) and EFPIA bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 16 September 2026, 10:30 (CEST) to 16 September 2026, 12:30 (CEST)
Ninth European Medicines Agency (EMA) and EFPIA bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 16 September 2026, 10:30 (CEST) to 16 September 2026, 12:30 (CEST)
Read →